<DOC>
	<DOCNO>NCT01477333</DOCNO>
	<brief_summary>The purpose multi-center , open-label , safety tolerability study assess addition oral treprostinil ( UT-15C sustain release [ SR ] tablet ) subject currently receive Tyvaso ( treprostinil ) inhalation solution . During 24-week evaluation period , study evaluate change follow assessment : hemodynamics , 6-minute walk test ( 6MWT ) , Borg dyspnea score , N-Terminal pro-brain natriuretic peptide ( NT-proBNP ) , World Health Organization ( WHO ) Functional Class , safety assessment . Eligible subject diagnosis pulmonary arterial hypertension ( PAH ) , currently receive Tyvaso , may receive approve PAH specific oral therapy ( endothelin receptor antagonist [ ERAs ] and/or phosphodiesterase type 5 inhibitor [ PDE5-I ] , stable dose ≥30 day ) . At Baseline , subject receive first dose 0.125 mg UT-15C SR .</brief_summary>
	<brief_title>Addition UT-15C SR Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>Significant inclusion criterion include : 1 . Subjects 18 75 year age 2 . Diagnosis PAH : Idiopathic ; Heritable ; Associated : Collagen vascular disease , Human immunodeficiency virus ( HIV ) infection , appetite suppressant toxin use , repair congenital systemictopulmonary shunt ( repair ≥5 year ) 3 . Had receive Tyvaso least 4 week ( ≥9 breath , 4 time day [ QID ] ) require additional therapy 4 . In addition Tyvaso , subject may receive approve PAH specific oral therapy ( ERAs and/or PDE5 inhibitor , stable dose ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Tyvaso</keyword>
	<keyword>UT-15C SR</keyword>
	<keyword>PAH</keyword>
</DOC>